Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

News Daily News

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

Caitlin E. Cox

July 14, 2025

News Daily News

Acoramidis Approved in Europe for ATTR Cardiomyopathy

Michael O'Riordan

February 12, 2025

News Daily News

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

L.A. McKeown

November 25, 2024

News Daily News

Biologic Winrevair Wins FDA Approval for Treatment of PAH

L.A. McKeown

March 27, 2024

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

News Daily News

FDA Grants First HF Indication for IV Iron to Ferric Carboxymaltose

Shelley Wood

June 05, 2023

News Daily News

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

Shelley Wood

May 30, 2023

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

News Daily News

Most Patient-Reported Outcome Measures in CVD Fall Short

L.A. McKeown

September 23, 2022

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Daily News

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

Yael L. Maxwell

July 09, 2021

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for March 2021

Shelley Wood

April 02, 2021

News Daily News

New FDA Indication Opens Up Use of Sacubitril/Valsartan in HFpEF

Todd Neale

February 16, 2021

News Daily News

FDA Approves Vericiguat for High-risk Patients With HF

Michael O'Riordan

January 20, 2021

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

L.A. McKeown

October 21, 2019

News Daily News

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

Michael O'Riordan

May 06, 2019

News Daily News

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

Todd Neale

October 12, 2018

Advertisement

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

Acoramidis Approved in Europe for ATTR Cardiomyopathy

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

Biologic Winrevair Wins FDA Approval for Treatment of PAH

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

FDA Grants First HF Indication for IV Iron to Ferric Carboxymaltose

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Most Patient-Reported Outcome Measures in CVD Fall Short

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

FDA Approves Empagliflozin for Treatment of HFpEF

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

FDA Approves Dapagliflozin for CKD Patients

TCTMD’s Top 10 Most Popular Stories for March 2021

New FDA Indication Opens Up Use of Sacubitril/Valsartan in HFpEF

FDA Approves Vericiguat for High-risk Patients With HF

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content